Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Rizos

Showing results (61-70 of 138) with videos related to

Pageof 14
Sort By:
Cancers|October 14, 2022
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response BiomarkersElena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, et al.
Cancers|April 30, 2021
Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C InhibitionJohn J Park, Russell J Diefenbach, Natalie Byrne, et al.
International Journal of Cancer|December 7, 2023
Ex vivo tissue modelling informs drug selection for rare cancersJenny H Lee, Zizhen Ming, Veronica K Y Cheung, et al.
The Journal of Investigative Dermatology|July 8, 2011
Selective loss of wild-type p16(INK4a) expression in human neviLyndee L Scurr, Heather A McKenzie, Therese M Becker, et al.
Cancer Chemotherapy and Pharmacology|January 21, 2019
Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexiaHannah Yejin Kim, Janna K Duong, Maria Gonzalez, et al.
Ebiomedicine|August 31, 2024
Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitorsSu Yin Lim, Yingxin Lin, Jenny H Lee, et al.
Cancer Cell International|November 26, 2025
Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanomaFei Yang, Su Yin Lim, Ines Pires da Silva, et al.
Plos One|April 16, 2014
Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signalingAndy J Chien, Lauren E Haydu, Travis L Biechele, et al.
The Journal of Investigative Dermatology|October 25, 2021
Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant MelanomaFarzana Ahmed, Hsin-Yi Tseng, Antonio Ahn, et al.
Neoplasia (New York, N.Y.)|October 28, 2008
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumorsStuart J Gallagher, John F Thompson, James Indsto, et al.
Pageof 14

Showing results (61-70 of 138) with videos related to

Sort By:
Pageof 14
Cancers|October 14, 2022
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response BiomarkersElena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, et al.
Cancers|April 30, 2021
Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C InhibitionJohn J Park, Russell J Diefenbach, Natalie Byrne, et al.
International Journal of Cancer|December 7, 2023
Ex vivo tissue modelling informs drug selection for rare cancersJenny H Lee, Zizhen Ming, Veronica K Y Cheung, et al.
The Journal of Investigative Dermatology|July 8, 2011
Selective loss of wild-type p16(INK4a) expression in human neviLyndee L Scurr, Heather A McKenzie, Therese M Becker, et al.
Cancer Chemotherapy and Pharmacology|January 21, 2019
Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexiaHannah Yejin Kim, Janna K Duong, Maria Gonzalez, et al.
Ebiomedicine|August 31, 2024
Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitorsSu Yin Lim, Yingxin Lin, Jenny H Lee, et al.
Cancer Cell International|November 26, 2025
Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanomaFei Yang, Su Yin Lim, Ines Pires da Silva, et al.
Plos One|April 16, 2014
Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signalingAndy J Chien, Lauren E Haydu, Travis L Biechele, et al.
The Journal of Investigative Dermatology|October 25, 2021
Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant MelanomaFarzana Ahmed, Hsin-Yi Tseng, Antonio Ahn, et al.
Neoplasia (New York, N.Y.)|October 28, 2008
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumorsStuart J Gallagher, John F Thompson, James Indsto, et al.
Pageof 14